Page 63 - GTM-2-2

Global Translational Medicine New insights into chronic pain management

23. Afari N, Ahumada SM, Wright LJ, et al., 2014, Psychological musculoskeletal pain conditions. Nat Rev Rheumatol,
trauma and functional somatic syndromes: A systematic 9: 340–350.
review and meta-analysis. Psychosom Med, 76: 2–11.
https://doi.org/10.1038/nrrheum.2013.43
https://doi.org/10.1097/PSY.0000000000000010
35. Huijnen IP, Rusu AC, Scholich S, et al., 2015, Subgrouping
24. Brennstuhl MJ, Tarquinio C, Montel S, 2014, Chronic pain of low back pain patients for targeting treatments: Evidence
and PTSD: Evolving views on their comorbidity. Perspect from genetic, psychological, and activity-related behavioral
Psychiatr Care, 51: 295–304. approaches. Clin J Pain, 31: 123–132.
https://doi.org/10.1111/ppc.12093 https://doi.org/10.1097/AJP.0000000000000100
25. Crombez G, Eccleston C, Van Damme S, et al., 2012, Fear- 36. Clauw DJ, 2015, Fibromyalgia and related conditions. Mayo
avoidance model of chronic pain: the next generation. Clin J Clin Proc, 90: 680–692.
Pain, 28: 475–483.
https://doi.org/10.1016/j.mayocp.2015.03.014
https://doi.org/10.1097/AJP.0b013e3182385392
37. Hauser W, Bernardy K, Uceyler N, et al., 2009, Treatment
26. Somers TJ, Wren AA, Shelby RA, 2012, The context of of fibromyalgia syndrome with antidepressants: A meta-
pain in arthritis: Self-efficacy for managing pain and other analysis. JAMA, 301: 198–209.
symptoms. Curr Pain Headache Rep, 16: 502–508.
https://doi.org/10.1001/jama.2008.944
https://doi.org/10.1007/s11916-012-0298-3
38. Mørk A, Pehrson A, Brennum LT, et al., 2012,
27. Wright LJ, Zautra AJ, Going S, 2008, Adaptation to early Pharmacological effects of Lu AA21004: A novel multimodal
knee osteoarthritis: the role of risk, resilience, and disease compound for the treatment of major depressive disorder.
severity on pain and physical functioning. Ann Behav Med, J Pharmacol Exp Ther, 340: 666–675.
36: 70–80.
https://doi.org/10.1124/jpet.111.189068
https://doi.org/10.1007/s12160-008-9048-5
39. Bang-Andersen B, Ruhland T, Jorgensen M, et al., 2011,
28. Edwards RR, Dworkin RH, Turk DC, et al., 2016, Patient Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]
phenotyping in clinical trials of chronic pain treatments: piperazine (Lu AA21004): A novel multimodal compound
IMMPACT recommendations. Pain, 157: 1851–1871. for the treatment of major depressive disorder. J Med Chem,
https://doi.org/10.1097/j.pain.0000000000000602 54: 3206–3221.
29. Edwards RR, Dworkin RH, Sullivan MD, et al., 2016, The https://doi.org/10.1021/jm101459g
role of psychosocial processes in the development and 40. Pehrson AL, Cremers T, Bétry C, et al., 2013, Lu AA21004,
maintenance of chronic pain. J Pain, 17: T70–T92. a novel multimodal antidepressant, produces regionally
https://doi.org/10.1016/j.jpain.2016.01.001 selective increases of multiple neurotransmitters-a
rat microdialysis and electrophysiology study. Eur
30. Turk DC, Fillingim RB, Ohrbach R, et al., Assessment of Neuropsychopharmacol, 23: 133–145.
psychosocial and functional impact of chronic pain. J Pain,
17: T21–T49. https://doi.org/10.1016/j.euroneuro.2012.04.006
https://doi.org/10.1016/j.jpain.2016.02.006 41. Sanchez C, Asin KE, Artigas F, 2015, Vortioxetine, a
novel antidepressant with multimodal activity: Review of
31. Burke AL, Mathias JL, Denson LA, 2015, Psychological preclinical and clinical data. Pharmacol Ther, 145: 43–57.
functioning of people living with chronic pain: A meta-
analytic review. Br J Clin Psychol, 54: 345–360. https://doi.org/10.1016/j.pharmthera.2014.07.001
https://doi.org/10.1111/bjc.12078 42. Stahl SM, 2015, Modes and nodes explain the mechanism
of action of vortioxetine, a multimodal agent (MMA):
32. Howe CQ, Robinson JP, Sullivan MD, 2015, Psychiatric
and psychological perspectives on chronic pain. Phys Med Enhancing serotonin release by combining serotonin (5HT)
Rehabil Clin N Am, 26: 283–300. transporter inhibition with action at 5HT receptors (5HT1A,
5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr, 20: 93–97.
https://doi.org/10.1016/j.pmr.2014.12.003
https://doi.org/10.1017/S1092852915000139
33. Fillingim RB, Ohrbach R, Greenspan JD, et al., 2013,
Psychological factors associated with development of TMD: 43. Cipriani A, Furukawa TA, Salanti G, et al., 2018, Comparative
The OPPERA prospective cohort study. J Pain, 14: T75–T90. efficacy and acceptability of 21 antidepressant drugs for the
acute treatment of adults with major depressive disorder:
https://doi.org/10.1016/j.jpain.2013.06.009 A systematic review and network meta-analysis. Lancet,
34. Diatchenko L, Fillingim RB, Smith SB, et al., 2013, 391: 1357–1366.
The phenotypic and genetic signatures of common https://doi.org/10.1016/S0140-6736(17)32802-7

Volume 2 Issue 2 (2023) 10 https://doi.org/10.36922/gtm.312